Pelthos Therapeutics Expands Its Dermatology Offerings
Pelthos Therapeutics Inc. (NYSE American: PTHS) has recently taken a significant step in enhancing its product line by acquiring the rights to Xepi® (ozenoxacin) Cream, 1%. This acquisition adds a vital dermatology product to Pelthos's existing portfolio, which is prominently anchored by ZELSUVMI™.
Introducing Xepi®: A Novel Treatment
Xepi is an FDA-approved topical solution designed specifically to combat impetigo, a common skin infection that often affects children due to antibiotic-resistant strains such as Staphylococcus aureus and Streptococcus pyogenes. Notably, nearly 3 million individuals in the United States are affected by this condition annually, making it one of the most frequent bacterial infections seen in pediatric care.
This acquisition allows Pelthos to directly address an urgent need in the medical community for effective treatments against antibiotic-resistant infections, signifying a leap forward in pediatric dermatology care.
Details of the Acquisition
Under the acquisition agreement, Pelthos will pay a total of approximately $4.2 million to Biofrontera Inc. and Ferrer Internacional S.A. This includes an upfront payment of $3 million to Biofrontera and an additional $1.2 million to Ferrer. Future milestone payments will depend on the production and sales of Xepi, along with a royalty on U.S. net sales of the product.
Funding the Future: Private Convertible Notes Financing
To facilitate this acquisition, Pelthos has also completed an $18 million financing through private convertible notes issued to a select group of investors, including Ligand Pharmaceuticals. This financial boost is expected to support the re-launch of Xepi and to expedite the commercialization of ZELSUVMI, which targets molluscum contagiosum, in addition to serving as working capital.
What This Means for Patients and Doctors
According to industry experts, the increasing resistance of bacteria to topical antibiotics currently in use underscores the need for new alternatives. In this context, Xepi offers a promising solution, particularly for pediatric patients who are often at risk for complications from traditional treatment failures.
“As we contend with rising resistance levels, the urgency for effective treatments is ever-present,” explains Dr. Lawrence A. Schachner, an authority in dermatology. He notes Xepi may become an essential tool in the treatment arsenal for children suffering from resistant strains of Staphylococcus aureus.
Looking Ahead: The Path for Pelthos
With this acquisition, Pelthos aims to leverage its already established commercial infrastructure to support multiple innovative brands moving forward. The company is enthusiastic about re-launching Xepi in the near future, allowing healthcare providers greater access to effective treatment options for their young patients.
“This acquisition is an exciting milestone for Pelthos and a stepping stone for our growth strategy,” says CEO Scott Plesha. By adding Xepi to our portfolio, we can further address the critical needs for pediatric dermatological care,” he adds.
Key Financial Information
The convertible notes issued are secured obligations with an interest rate of 8.5% per year, and they will mature in November 2027 unless repurchased or converted. The company anticipates utilizing the financing proceeds efficiently to augment its operational capabilities, strengthen its portfolio, and sustain robust commercial growth.
Frequently Asked Questions
What is the significance of Pelthos's acquisition of Xepi?
This acquisition significantly enhances Pelthos's portfolio by adding an effective treatment for impetigo, addressing critical patient needs in pediatric dermatology.
How will Pelthos fund the acquisition of Xepi?
Pelthos secured $18 million in funding through private convertible notes financing aimed at supporting both Xepi's acquisition and the commercialization of ZELSUVMI.
What are the expected benefits of Xepi for patients?
Xepi offers a novel treatment option that targets antibiotic-resistant strains commonly affecting children, potentially leading to better treatment outcomes.
When does Pelthos plan to re-launch Xepi?
Pelthos intends to re-launch Xepi in late 2026, allowing more access to this important treatment for healthcare providers and their patients.
What are the implications of rising antibiotic resistance in pediatric care?
Rising antibiotic resistance makes it crucial to develop and provide new treatment options, like Xepi, which are effective against resistant strains, ensuring better healthcare outcomes for affected children.
